Αποτελέσματα Αναζήτησης
ORTHO EVRA® is a combination transdermal contraceptive patch with a contact surface area of 20 cm2. It contains 6.00 mg norelgestromin (NGMN) and 0.75 mg ethinyl estradiol (EE).
1. NAME OF THE MEDICINAL PRODUCT. EVRA 203 micrograms/24 hours + 33.9 micrograms/24 hours transdermal patch. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION. Each 20 cm2 transdermal patch contains 6 mg norelgestromin (NGMN) and 600 micrograms ethinyl estradiol (EE).
ORTHO EVRA® is a combination transdermal contraceptive patch with a contact surface area of 20 cm 2 .It contains 6.00 mg norelgestromin and 0.75 mg ethinyl estradiol (EE),and releases 150 micrograms of norelgestromin and 20 micrograms of EE to the bloodstream per 24 hours.
The EVRA® (norelgestromin and ethinyl estradiol) transdermal system is indicated for the prevention of pregnancy. The pharmacokinetic profile for the EVRA® transdermal system is different from that of an oral contraceptive. The clinical relevance of the differences in PK profiles between
EVRA contains two types of sex hormones, a progestogen called norelgestromin and an oestrogen called ethinyl estradiol. Because it contains two hormones, EVRA is called a ‘combined hormonal contraceptive’.
Evra is a transdermal patch version of ‘the pill’ (combined oral contraceptive tablet). Using a weekly transdermal patch instead of a daily pill may help the woman to stick to using her contraception appropriately.
The EVRA (norelgestromin and ethinyl estradiol) transdermal system, with a contact surface area of 20 cm2, is a thin, matrix-type transdermal system consisting of three layers. Each transdermal system contains 6.0 mg norelgestromin and 0.60 mg ethinyl estradiol (EE).
